PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
Status:
Recruiting
Trial end date:
2029-08-31
Target enrollment:
Participant gender:
Summary
PRIMETEST II is an interventional study involving low-volume metastatic seminoma. It explores
a novel approach using robot-assisted primary retroperitoneal lymph node dissection, aiming
to reduce long-term side effects and improve quality of life. By identifying factors
predicting cancer recurrence, the study hopes to tailor treatments for better outcomes. The
approach could potentially spare patients from chemotherapy induced long-term side effects
while maintaining excellent survival rates, presenting a promising shift in testicular cancer
care for this specific patient group.